WO2000001716A2 - Vasculoprotector - Google Patents
Vasculoprotector Download PDFInfo
- Publication number
- WO2000001716A2 WO2000001716A2 PCT/GB1999/002157 GB9902157W WO0001716A2 WO 2000001716 A2 WO2000001716 A2 WO 2000001716A2 GB 9902157 W GB9902157 W GB 9902157W WO 0001716 A2 WO0001716 A2 WO 0001716A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agonist
- vasculoprotective
- effect
- erβ
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99929579A EP1094806A2 (en) | 1998-07-06 | 1999-07-06 | Vasculoprotector |
CA002331885A CA2331885A1 (en) | 1998-07-06 | 1999-07-06 | Vasculoprotector |
AU46364/99A AU4636499A (en) | 1998-07-06 | 1999-07-06 | Vasculoprotector |
JP2000558117A JP2002519435A (en) | 1998-07-06 | 1999-07-06 | Vascular protective agent |
KR1020017000141A KR20010079495A (en) | 1998-07-06 | 1999-07-06 | Vasculoprotector |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9814620.2 | 1998-07-06 | ||
GBGB9814620.2A GB9814620D0 (en) | 1998-07-06 | 1998-07-06 | Vasculoprotector |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000001716A2 true WO2000001716A2 (en) | 2000-01-13 |
WO2000001716A3 WO2000001716A3 (en) | 2000-10-05 |
Family
ID=10835023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/002157 WO2000001716A2 (en) | 1998-07-06 | 1999-07-06 | Vasculoprotector |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1094806A2 (en) |
JP (1) | JP2002519435A (en) |
KR (1) | KR20010079495A (en) |
AU (1) | AU4636499A (en) |
CA (1) | CA2331885A1 (en) |
GB (1) | GB9814620D0 (en) |
WO (1) | WO2000001716A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000016759A2 (en) * | 1998-09-17 | 2000-03-30 | Guido Schnyder | Genistein for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty |
WO2002046168A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
US6794403B2 (en) | 2001-12-05 | 2004-09-21 | Wyeth | Substituted benzoxazoles as estrogenic agents |
US6835745B2 (en) | 2002-01-15 | 2004-12-28 | Wyeth | Phenyl substituted thiophenes as estrogenic agents |
US7354927B2 (en) | 2004-09-07 | 2008-04-08 | Wyeth | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents |
US7674783B2 (en) | 2002-11-22 | 2010-03-09 | Dimera Inc. | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008174463A (en) * | 2007-01-16 | 2008-07-31 | Ankhs:Kk | TGF-beta SIGNAL TRANSMISSION MECHANISM INHIBITOR, SMAD DEGRADATION INDUCTOR, SMAD UBIQUITIN FORMATION PROMOTER, SMURF DEGRADATION INDUCTOR, SMURF UBIQUITIN FORMATION PROMOTER, METHOD FOR INHIBITING TGF-beta SIGNAL TRANSMISSION MECHANISM, METHOD FOR INDUCING SMAD DEGRADATION, METHOD FOR PROMOTING SMAD UBIQUITIN FORMATION, METHOD FOR INDUCING SMURF DEGRADATION, AND METHOD FOR PROMOTING SMURF UBIQUITIN FORMATION |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993023090A1 (en) * | 1992-05-20 | 1993-11-25 | Sherwood Medical Company | Artificial blood vessel |
WO1997009348A2 (en) * | 1995-09-08 | 1997-03-13 | Karo Bio Ab | Orphan receptor |
WO1998008503A1 (en) * | 1996-08-30 | 1998-03-05 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
US5919813A (en) * | 1998-03-13 | 1999-07-06 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3476604B2 (en) * | 1995-08-22 | 2003-12-10 | 鐘淵化学工業株式会社 | Method for manufacturing stent with drug attached / coated |
JP2829388B2 (en) * | 1996-09-27 | 1998-11-25 | 農林水産省四国農業試験場長 | Composition for promoting cell differentiation into fat cells |
JPH11139974A (en) * | 1997-11-07 | 1999-05-25 | Kureha Chem Ind Co Ltd | Tissue fibrosis suppressant |
-
1998
- 1998-07-06 GB GBGB9814620.2A patent/GB9814620D0/en not_active Ceased
-
1999
- 1999-07-06 KR KR1020017000141A patent/KR20010079495A/en not_active Application Discontinuation
- 1999-07-06 AU AU46364/99A patent/AU4636499A/en not_active Abandoned
- 1999-07-06 CA CA002331885A patent/CA2331885A1/en not_active Abandoned
- 1999-07-06 JP JP2000558117A patent/JP2002519435A/en active Pending
- 1999-07-06 EP EP99929579A patent/EP1094806A2/en not_active Withdrawn
- 1999-07-06 WO PCT/GB1999/002157 patent/WO2000001716A2/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993023090A1 (en) * | 1992-05-20 | 1993-11-25 | Sherwood Medical Company | Artificial blood vessel |
WO1997009348A2 (en) * | 1995-09-08 | 1997-03-13 | Karo Bio Ab | Orphan receptor |
WO1998008503A1 (en) * | 1996-08-30 | 1998-03-05 | Novogen Research Pty. Ltd. | Therapeutic methods and compositions involving isoflavones |
US5919813A (en) * | 1998-03-13 | 1999-07-06 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
US5919813C1 (en) * | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
Non-Patent Citations (15)
Title |
---|
BALARAM S.K. ET AL: "Cell adhesion molecules and insulin-like growth factor-1 in vascular disease." JOURNAL OF VASCULAR SURGERY, (1997) 25/5 (866-876)., XP002126538 * |
BECKELER, KLAUS ET AL: "Differential effects of immunosuppressive cyclosporine A and inhibitors of protein kinases on cytokine induced cell proliferation of umbilical cord artery smooth muscle cells: The role of endothelial supernatants on TNF-alpha effects." EUROPEAN JOURNAL OF CELL BIOLOGY, (1996) VOL. 69, NO. SUPPL. 42, PP. 126. MEETING INFO.: 21ST ANNUAL MEETING OF THE GERMAN SOCIETY FOR CELL BIOLOGY HAMBURG, GERMANY MARCH 24-28, 1996, XP002126534 * |
CLARKSON T.B. ET AL: "The nonhuman primate model of the relationship between gonadal steroids and coronary heart disease." PROGRESS IN CARDIOVASCULAR DISEASES, (1995) 38/3 (189-198)., XP002126540 * |
DATABASE WPI Section Ch, Week 199720 Derwent Publications Ltd., London, GB; Class A96, AN 1997-215838 XP002126543 & JP 09 056807 A (KANEBUCHI KAGAKU KOGYO KK), 4 March 1997 (1997-03-04) * |
DATABASE WPI Section Ch, Week 199826 Derwent Publications Ltd., London, GB; Class B02, AN 1998-292041 XP002126542 & JP 10 101561 A (SHIKOKU NOGYO SHIKENJO), 21 April 1998 (1998-04-21) * |
DATABASE WPI Section Ch, Week 199932 Derwent Publications Ltd., London, GB; Class B02, AN 1999-374524 XP002126544 & JP 11 139974 A (KUREHA CHEM IND CO LTD), 25 May 1999 (1999-05-25) * |
HONORE E K ET AL: "Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques." FERTILITY AND STERILITY, (1997 JAN) 67 (1) 148-54., XP002126539 * |
KAPIOTIS S ET AL: "Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL." ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, (1997 NOV) 17 (11) 2868-74., XP002126537 * |
KUIPER ET AL.: "Comparison of the ligand Binding Specificity and Transcript Distribution of Estrogen Receptors alpha and beta" ENDOCRINOLOGY, vol. 138, no. 3, 1997, pages 863-870, XP002126536 cited in the application * |
LINDNER, VOLKHARD ET AL: "Increased expression of estrogen receptor -. beta. mRNA in male blood vessels after vascular injury" CIRC. RES. (1998), 83(2), 224-229, XP000856530 * |
M S ANTHONY ET AL: "Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys" JOURNAL OF NUTRITION,XX,XX, vol. 126, no. 1, page 43-50 XP002095625 ISSN: 0022-3166 * |
ST CLAIR R.W.: "Estrogens and atherosclerosis: Phytoestrogens and selective estrogen receptor modulators." CURRENT OPINION IN LIPIDOLOGY, (1998) 9/5 (457-463)., XP002126541 * |
TAKAMURA, HIROYUKI: "Immunosuppressive effects of a tyrosine kinase specific inhibitors ( genistein ) on the rejection of rat allogeneic small bowel transplantation" KANAZAWA DAIGAKU JUZEN IGAKKAI ZASSHI (1995), 104(6), 719-731, XP002126533 * |
TROVATI M. ET AL: "Insulin increases cyclic nucleotide content in human vascular smooth muscle cells: A mechanism potentially involved in insulin-induced modulation of vascular tone." DIABETOLOGIA, (1995) 38/8 (936-941)., XP002126535 * |
WILLIAMS J.K. ET AL: "Estrogens, progestins, and coronary artery reactivity in atherosclerotic monkeys." JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, (1998) 65/1-6 (219-224)., XP002126532 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000016759A2 (en) * | 1998-09-17 | 2000-03-30 | Guido Schnyder | Genistein for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty |
WO2000016759A3 (en) * | 1998-09-17 | 2000-05-25 | Guido Schnyder | Genistein for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty |
WO2002046168A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
US6794403B2 (en) | 2001-12-05 | 2004-09-21 | Wyeth | Substituted benzoxazoles as estrogenic agents |
US7129258B2 (en) | 2001-12-05 | 2006-10-31 | Wyeth | Substituted benzoxazoles as estrogenic agents |
US7148247B2 (en) | 2001-12-05 | 2006-12-12 | Wyeth | Substituted benzoxazoles as estrogenic agents |
US7531564B2 (en) | 2001-12-05 | 2009-05-12 | Wyeth | Substituted benzoxazoles as estrogenic agents |
US6835745B2 (en) | 2002-01-15 | 2004-12-28 | Wyeth | Phenyl substituted thiophenes as estrogenic agents |
US7674783B2 (en) | 2002-11-22 | 2010-03-09 | Dimera Inc. | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease |
US7354927B2 (en) | 2004-09-07 | 2008-04-08 | Wyeth | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents |
Also Published As
Publication number | Publication date |
---|---|
AU4636499A (en) | 2000-01-24 |
CA2331885A1 (en) | 2000-01-13 |
EP1094806A2 (en) | 2001-05-02 |
GB9814620D0 (en) | 1998-09-02 |
JP2002519435A (en) | 2002-07-02 |
KR20010079495A (en) | 2001-08-22 |
WO2000001716A3 (en) | 2000-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fu et al. | HIF-1α-BNIP3-mediated mitophagy in tubular cells protects against renal ischemia/reperfusion injury | |
Barha et al. | Progesterone treatment normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus after traumatic brain injury | |
McEwen et al. | The brain as a target for steroid hormone action | |
Fan et al. | 17β-estradiol on the expression of G-protein coupled estrogen receptor (GPER/GPR30) mitophagy, and the PI3K/Akt signaling pathway in ATDC5 chondrocytes in vitro | |
Mathews et al. | Paradoxical hypermasculinization of the zebra finch song system by an antiestrogen | |
Wolf et al. | Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice | |
Benoit et al. | Estetrol, a fetal selective estrogen receptor modulator, acts on the vagina of mice through nuclear estrogen receptor α activation | |
JP2000510460A (en) | Treatment of epithelial malignancies using squalamine in combination with other anticancer drugs | |
JP2001506638A (en) | How to prevent or control cataracts | |
Holder et al. | Methamphetamine-enhanced female sexual motivation is dependent on dopamine and progesterone signaling in the medial amygdala | |
DiMusto et al. | Increased JNK in males compared with females in a rodent model of abdominal aortic aneurysm | |
Storment et al. | Estrogen augments the vasodilatory effects of vascular endothelial growth factor in the uterine circulation of the rat | |
JP2003509456A (en) | Local delivery of 17-β estradiol to prevent intimal thickening and improve vascular endothelial function after vascular injury | |
Turi et al. | Estrogen downregulates the number of caveolae and the level of caveolin in uterine smooth muscle | |
Takaoka et al. | Oestrogen protects against ischaemic acute renal failure in rats by suppressing renal endothelin-1 overproduction | |
EP1094806A2 (en) | Vasculoprotector | |
Xu et al. | Pharmacology-based molecular docking of 4-methylcatechol and its role in RANKL-mediated ROS/Keap1/Nrf2 signalling axis and osteoclastogenesis | |
Gérard et al. | Estetrol: from preclinical to Clinical Pharmacology and advances in the understanding of the molecular mechanism of action | |
Rudzitis-Auth et al. | Inhibition of cyclooxygenase-2 suppresses the recruitment of endothelial progenitor cells in the microvasculature of endometriotic lesions | |
TW200845989A (en) | Medicament for the treatment of endometriosis | |
Chen et al. | Basic fibroblast growth factor protects against liver ischemia-reperfusion injury via the Nrf2/Hippo signaling pathway | |
CN107007611B (en) | Application of nomegestrol acetate in preparation of medicine for treating endometrial cancer | |
Love et al. | Tamoxifen therapy in breast cancer control worldwide. | |
de Azevedo Camin et al. | Effects of maternal exposure to the galactagogue Sulpiride on reproductive parameters in female rats | |
AU2004200635A1 (en) | Vasculoprotector |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP KR NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP KR NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999929579 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 46364/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2331885 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017000141 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 558117 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1999929579 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09719658 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017000141 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017000141 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999929579 Country of ref document: EP |